Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs

About this update from Cybin, Inc.

[{"type":"text","content":"Cybin Inc protects IP with granting of 2nd US Patent for its deuterated analog programs\n \n \n (NewsDirect)\n \n \n \n \n Cybin Inc CEO Doug Drysdale joined Steve\nDarling from Proactive to share news the US Patent and Trademark\nOffice has granted another patent to a deuterated psilocybin analog\nwithin the company's CYB003 investigational drug program.\n \n \n This patent is expected to provide\nexclusivity until 2041 and encompasses composition of matter claims\nfor deuterated tryptamines. These claims support various programs\nwithin Cybin, including CYB003, a deuterated psilocybin analog, and\nCYB004, a deuterated dimethyltryptamine. The patent also covers\nmethods of treating major depressive disorder and treatment-resistant\ndepression.\n \n \n Drysdale explained that\nCYB003 is a proprietary deuterated psilocybin analog developed for the\npotential treatment of major depressive disorder. The deuterated\nstructure of CYB003 aims to optimize its therapeutic profile,\nincluding rapid onset of effect, shorter treatment duration, and\nefficacy at lower doses.\n \n \n Currently,\nCYB003 is undergoing Phase 2 clinical trials involving participants\nwith moderate to severe MDD. Additionally, Drysdale mentioned CYB004,\nan investigational deuterated dimethyltryptamine program targeted for\nthe potential treatment of Generalized Anxiety Disorder.\n \n \n This program is in Phase 1, with dosing\nunderway as part of the CYB004-E clinical trial evaluating intravenous\nDMT and CYB004 in healthy volunteers.\n \n \n Cybin Inc anticipates\nreleasing topline Phase 2 efficacy data for CYB003 in MDD and Phase 1\ndata from the CYB004-E study in the third or fourth quarter of 2023.\n \n \n \n Contact Details\n \n \n \n Proactive Investors\n \n \n +1\n604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":2351,"tagName":"div"}]

More updates from Cybin, Inc.